Abstract | BACKGROUND AND PURPOSE: MATERIALS AND METHODS: RESULTS: Amuvaninib inhibited RAD51 protein expression and HR. This was associated with reduced ribosomal protein S6 phosphorylation and inhibition of global translation. Amuvatinib sensitized cells to IR and MMC, agents that are selectively toxic to HR-deficient cells. CONCLUSIONS:
Amuvatinib is a promising agent that may be used to decrease tumor cell resistance. Our work suggests that this is associated with decreased RAD51 expression and function and supports the further study of amuvatinib in combination with chemotherapy and radiotherapy.
|
Authors | Helen Zhao, Kaisa R Luoto, Alice X Meng, Robert G Bristow |
Journal | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
(Radiother Oncol)
Vol. 101
Issue 1
Pg. 59-65
(Oct 2011)
ISSN: 1879-0887 [Electronic] Ireland |
PMID | 21903282
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Piperazines
- Pyrimidines
- Radiation-Sensitizing Agents
- Receptor Protein-Tyrosine Kinases
- Rad51 Recombinase
- Thiourea
- amuvatinib
|
Topics |
- Dose-Response Relationship, Drug
- Dose-Response Relationship, Radiation
- Homologous Recombination
(drug effects, genetics, radiation effects)
- Humans
- Lung Neoplasms
(drug therapy, genetics, radiotherapy)
- Phosphorylation
- Piperazines
- Pyrimidines
(pharmacology)
- Rad51 Recombinase
(drug effects, genetics, radiation effects)
- Radiation Tolerance
(drug effects)
- Radiation, Ionizing
- Radiation-Sensitizing Agents
(pharmacology)
- Real-Time Polymerase Chain Reaction
- Receptor Protein-Tyrosine Kinases
(antagonists & inhibitors)
- Thiourea
- Tumor Cells, Cultured
|